The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database

Background: To evaluate the performance of the 21-gene recurrence score (RS) assay in predicting chemotherapy benefit in the Surveillance, Epidemiology, and End Results population, we aimed to assess breast cancer-specific mortality (BCSM) by chemotherapy use within each of the RS categories. Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, In Sil, Jung, Jiwoong, Kim, Byoung Hyuck, Oh, Sohee, Kim, Jongjin, Park, Jin Hyun, Park, Jeong Hwan, Hwang, Ki-Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408834/
https://www.ncbi.nlm.nih.gov/pubmed/32650374
http://dx.doi.org/10.3390/cancers12071829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408834/
https://www.ncbi.nlm.nih.gov/pubmed/32650374
http://dx.doi.org/10.3390/cancers12071829

Ejemplares similares